Tender Details

Country: Germany
Summary: Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Formoterol Beclometasone (Exclusively Dafo. Ihp, Inh), Atc R03ak08 for the Period January 1St, 2024 - December 31St, 2025
DET Ref No: 92346347
Deadline: 05 Dec 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: EUR 1.00
Notice Type: Tender
Document Ref. No.: 695520-2023
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Section 130a paragraph 8 SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount agreements for the medicines to be supplied at the expense of the statutory health insurance companies. With regard to the relevant legal regulations for the award of public contracts, seeet a regular process of active ingredient-related, formal award procedures takes place in accordance with the regulations of Part 4 of the GWB by DAK-Gesundheit. For medicinal products to be specified by the bidder in Annex 2 to the contract in relation to the above. Active ingredient, formoterol beclometasone (exclusively dosagengforms IHP, INH), ATC R03AK08, DAK-Gesundheit intends to conclude drug discount agreements with as many interested pharmaceutical companies as possible until new drug discount agreements come into force. A discount contract in the form of an approval model for the above-mentioned. Active ingredient occurscame into force for the first time on January 1st, 2024 and ends on December 31st, 2025. Regardless, it ends automatically when the exclusive contract comes into force.
Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient formoterol beclometasone (exclusively Dafo. IHP, INH), ATC R03AK08 ffor the period January 1st, 2024 - December 31st, 2025
Doc Title: Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient formoterol beclometasone (exclusively Dafo. IHP, INH), ATC R03AK08 for the period January 1st, 2024 - 12/31/2025
Contract Type: supplies
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Formoterol Beclometasone (Exclusively Dafo. Ihp, Inh), Atc R03ak08 for the Period January 1St, 2024 - December 31St, 2025 - Germany Tender

The DAK HEALTH, a Government sector organization in Germany, has announced a new tender for Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Formoterol Beclometasone (Exclusively Dafo. Ihp, Inh), Atc R03ak08 for the Period January 1St, 2024 - December 31St, 2025. This tender is published on GermanyTenders under DET Ref No: 92346347 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-12-05.

The estimated tender value is EUR 1.00, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.